0
0
Read Time:9 Minute, 31 Second
The Indonesia In vitro Diagnostics Market is Expected to Grow at a CAGR of 10.6% from 2022 to 2029 to Reach $1.11 Billion by 2029, according to Meticulous Research®. The growth of the Indonesia In vitro diagnostics market is driven by the increasing prevalence of infectious and chronic diseases and the Government’s initiatives for strengthening the country’s healthcare ecosystem. Additionally, the rising demand for quality healthcare in the country is expected to create market growth opportunities in the In vitro diagnostics market in Indonesia.
Here are the top 10 companies operating in the Indonesia In Vitro Diagnostics Market
F. Hoffman-La Roche Ltd. (Switzerland)
Incorporated in 1896 and headquartered in Basel, Switzerland, F. Hoffmann is a research-based healthcare company engaged in developing innovative medicines and providing solutions for diagnostics. The company operates through two business segments, namely, Pharmaceuticals and Diagnostics. The company manufactures equipment & reagents for research & medical diagnostic applications through its Diagnostics segment. This segment is further categorized into Core Lab, Molecular Lab, Point of Care, Diabetes Care, and Pathology Lab. The company offers IVD products such as centralized and point-of-care kits & reagents, advanced staining reagents, molecular diagnostic tests, and blood screening tests through its Diagnostics segment. Roche has 20 manufacturing sites and 27 R&D sites engaged in pharmaceuticals and diagnostics operations worldwide. The company operates in the Indonesia IVD market through its subsidiary P.T. Roche Indonesia (Indonesia).
Thermo Fisher Scientific Inc. (U.S.)
Founded in 2006 and headquartered in Massachusetts, U.S., Thermo is a biotechnology company engaged in life sciences research, improving patient diagnostics, and increasing laboratory productivity. The company operates through four business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The company offers diagnostic test kits, reagents, culture media, instruments, and associated products for customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories through its Specialty Diagnostics segment. This segment is further subsegmented into five primary businesses: Clinical Diagnostics, Immunodiagnostics, Microbiology, Transplant Diagnostics, and Healthcare Market Channel. The company has its regional offices and production sites in various countries, including the U.S., Mexico, Brazil, Germany, Belgium, Austria, the U.K., Italy, the Netherlands, South Africa, UAE, India, Indonesia, China, Japan, Australia, and the Republic of Korea. Some of the company’s distributors in Indonesia are PT. Genecraft Labs, PT. Karunia Jasindo, and PT. Elo Karsa Utama.
Abbott Laboratories, Inc. (U.S.)
Founded in 1888 and headquartered in Illinois, U.S., Abbott Laboratories is engaged in discovering, developing, manufacturing, and selling healthcare products. The company offers a wide range of products to the diagnostics, medical devices, nutrition, and branded generic pharmaceuticals markets. The company operates worldwide through four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Through the Diagnostic Products segment, the company provides a broad range of diagnostic systems and tests, which are manufactured, marketed, and sold worldwide to blood banks, hospitals, commercial laboratories, clinics, retailers, government agencies, alternate care testing sites, and plasma protein therapeutic companies. This segment is further subsegmented into six business categories: Core Laboratory, Molecular Diagnostics, Point of Care, Informatics, Automation Solutions, and Rapid Diagnostics.
The company has a geographical presence and a strong distribution network in various countries through direct and indirect channels. Additionally, it has 90 manufacturing facilities globally, of which 24 manufacturing sites are engaged in developing diagnostic products. The company operates in the Indonesia IVD market through its distributors, such as PT. Itama Ranoraya Tbk.
Danaher Corporation (U.S.)
Founded in 1969 and headquartered in Washington, D.C., U.S., Danaher Corporation is engaged in designing, manufacturing, and marketing medical, professional, industrial, and commercial products and services for various end users. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions.
The company operates in the IVD market through its Diagnostics segment. The products offered by this segment are used in various healthcare settings such as hospitals, reference laboratories, and other critical care settings to diagnose diseases. The Diagnostics segment is further subsegmented into four businesses: Core Lab– Clinical, Molecular Diagnostics, Acute Care Diagnostics, and Pathology Diagnostics.
Danaher has a total of 212 R&D, manufacturing, sales, distribution, service, and administrative facilities in more than 60 countries worldwide. The company’s manufacturing facilities are located in North America, Europe, Asia, and Australia. The company operates in the Indonesia IVD market through its subsidiaries Beckman Coulter (distributor: PT. Enseval Medika Prima), Radiometer Medical ApS (distributor: PT. Abadinusa Usahasemesta), and Cepheid (distributor: PT. Medquest Jaya Global).
Becton, Dickinson and Company (U.S.)
Founded in 1887 and headquartered in New Jersey, U.S., Becton, Dickinson and Company is a medical technology company that manufactures and sells a wide range of medical devices, laboratory equipment, and diagnostic products used by healthcare institutions, clinical laboratories, pharmaceutical companies, and research centers. The company operates through three business segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Life Sciences segment offers products in two major categories: Integrated Diagnostic Solutions (Diagnostic Systems and Preanalytical Systems) and Biosciences. The Diagnostic Systems category offers numerous products for clinical and industrial applications. These products include molecular testing systems for infectious diseases & women’s health, liquid-based cytology systems for cervical cancer screening, culturing systems, rapid diagnostic assays for testing respiratory infections, microorganism identification, and drug susceptibility systems.
The company has a wide global distribution network and markets its products through independent distribution channels and directly to hospitals, healthcare institutions, and independent sales representatives. BD operates in the Indonesia IVD market through its distributor Everest Trade Link (Indonesia).
Meticulous Research in its latest publication on Indonesia In Vitro Diagnostics Market has predicted the growth of 10.6% during the forecast year 2022-2029.
Bio-Rad Laboratories, Inc. (U.S.)
Founded in 1952 and headquartered in California, U.S., Bio-Rad is engaged in developing and producing specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. Its products are used by various life science research, healthcare, and analytical chemistry end users.
The company operates through two business segments: Life Science and Clinical Diagnostics. The company offers IVD test kits, systems, quality control products and services, and related informatics systems through its Clinical Diagnostics segment. The company supplies over 3,000 products, covering more than 300 clinical diagnostic tests in the IVD market. Reference laboratories, hospital laboratories, transfusion laboratories, and physician office laboratories are some of the company’s major customers in the IVD market.
The company has manufacturing and research facilities in the U.S., France, Belgium, Switzerland, and Germany for the Clinical Diagnostics business segment. Bio-Rad has direct distribution channels in 35 countries outside the U.S. Bio-Rad operates in the Indonesia IVD market through its subsidiary PT. Becton Dickinson Indonesia.
Incorporated in 1999 and headquartered in California, U.S., Agilent Technologies provides application-focused solutions to the life sciences, diagnostics, and applied chemical markets. The company operates through three business segments: Life Sciences & Applied Markets, Diagnostics and Genomics, and Agilent CrossLab Business. The company offers IVD solutions under its Diagnostics and Genomics segment. This business segment is engaged in genomics, nucleic acid contract manufacturing and R&D, pathology, companion diagnostics, and biomolecular analysis businesses.
Agilent has R&D and manufacturing sites across the U.S., Australia, China, Denmark, Germany, Italy, Japan, Malaysia, Belgium, Singapore, and the U.K. The company operates in the Indonesia IVD market through distributors such as PT. Vision Teknik and PT. Elo Karsa Utama.
PerkinElmer, Inc. (U.S.)
Founded in 1947 and headquartered in Massachusetts, U.S., PerkinElmer provides products, solutions, and services for life sciences, solutions, and applied markets. The company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The company offers IVD products through its Diagnostic segment. This segment also offers reagents, instruments, assay platforms, and software to medical research professionals, hospitals, clinicians, and medical laboratories.
The company operates directly in 38 countries and provides services in more than 190 countries. The company operates in the Indonesia IVD market through its distributor PT. Perkindo Mitra Analitika.
Established in 1968 and headquartered in Hyogo, Japan, Sysmex is engaged in providing clinical IVD and health IT products and services for clinical laboratories, hospitals and other healthcare organizations. The company operates through four business segments: Diagnostics, Life Science, Medical Robot Business, and Other fields. The company provides products for the IVD market through its Diagnostics segment, which includes solutions for clinical laboratory testing across hematology, hemostasis, urinalysis, clinical chemistry, immunoassay system, flow cytometry, and life sciences.
With customers in more than 190 countries, Sysmex has a wide geographic presence through its subsidiaries across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. The company’s R&D facilities are located in Europe, the U.S., China, and other countries. Some of the major subsidiaries of the company are Sysmex America, Inc. (U.S.), Sysmex Canada, Inc. (Canada), Sysmex France S.A.S. (France), Sysmex UK Limited (U.K.), and Sysmex Asia Pacific Pte Ltd. (Singapore), among others. The company operates in the Indonesia IVD market through its subsidiary PT. Sysmex Indonesia.
Siemens Healthineers (Germany)
Founded in 1847 and headquartered in Erlangen, Germany, Siemens Healthineers AG is engaged in developing and selling a wide range of products with medical imaging applications, laboratory diagnostics, and point-of-care testing. The company also offers digital health platforms for various clinical specialties and laboratory diagnostic services globally. The company operates through three business segments: Imaging, Diagnostics, and Varian and Advanced Therapies. The company offers IVD products and services to healthcare professionals working in molecular diagnostics, point-of-care diagnostics, and laboratories through its Diagnostics segment.
The company has a direct presence in more than 70 countries, including the U.S., Canada, Germany, the U.K., France, Italy, Spain, Denmark, Sweden, Switzerland, Belgium, India, China, Japan, Australia, New Zealand, the Republic of Korea, and other European countries. The company operates in the Indonesia IVD market through its distributor East West Group (Indonesia).
Founded in 1984 and headquartered in Venlo, Netherlands, QIAGEN N.V. develops & sells instruments, consumables, and digital bioinformatics solutions for oncology, infectious diseases, sexual & reproductive health, tuberculosis (TB) management, precision diagnostics, and point of care testing research. The company operates in two business segments: Molecular Diagnostics and Life Sciences. The company offers a wide range of molecular diagnostic technologies through its Molecular Diagnostics segment, including automated systems, assays, markers, and reagents used to diagnose cancer and infectious diseases.
The company offers its products to more than 500,000 customers and has 35 subsidiaries operating in 35 countries, including the U.S., Canada, Germany, Spain, the U.K., France, Italy, the Netherlands, Sweden, Turkey, Sweden, Brazil, Mexico, China, Hong Kong, Taiwan, South Korea, India, and South Africa. The company has a strong distribution network with partners across 60 countries worldwide. Some of its distributors in Indonesia are PT. GeneCraft Labs, PT. InoDia, and PT. UBC Medical Indonesia.
Authoritative Research on the Indonesia IVD Market – Regional Opportunity Analysis and Industry Forecast (2022-2029)
Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:
- Recent financial performance
- Key products
- Significant company strategies
- Partnerships and acquisitions
The Comprehensive report provides indonesia market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
